CJC-1295 Research Overview

An overview of CJC-1295, a modified GHRH analogue with extended duration of action, and its research applications.

Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.

Novex Peptide Research Team1 August 2026 7 min read

CJC-1295 GHRH growth hormone DAC IGF-1

Introduction

CJC-1295 is a synthetic modification of growth hormone-releasing hormone (GHRH) designed to extend its biological half-life. The modification involves adding a drug affinity complex (DAC) that binds to serum albumin, significantly increasing the peptide's duration of action compared to native GHRH.

Mechanism of Action

GHRH Receptor Agonism

CJC-1295 binds to and activates the GHRH receptor in the anterior pituitary, stimulating pulsatile growth hormone release.

Albumin Binding

The DAC modification allows CJC-1295 to bind to serum albumin, extending its half-life from minutes to approximately 8 days in animal models. This extended half-life allows for less frequent administration in research protocols.

IGF-1 Elevation

Through sustained GH release, CJC-1295 elevates IGF-1 levels, which mediates many of the anabolic and metabolic effects studied in research.

Current Research

Growth Hormone Research

Animal studies have used CJC-1295 to investigate the effects of sustained, pulsatile GH release on body composition, muscle mass, and bone density.

Combination Research

Research has explored combining CJC-1295 with GH secretagogues (such as ipamorelin) to study potential synergistic effects on GH release through complementary pathways.

Metabolic Research

Studies have investigated CJC-1295's effects on lipid metabolism, glucose homeostasis, and protein synthesis in animal models.

Chemical Properties

**Sequence:** Modified 30-amino acid GHRH analogue with DAC

**Molecular weight:** 3,917.6 Da (CJC-1295 with DAC)

**Modification:** Drug Affinity Complex (DAC) at C-terminus for albumin binding

**Half-life:** ~8 days in animal models (vs. ~7 minutes for native GHRH)

Storage Considerations

Store lyophilised CJC-1295 at -20°C.

Protect from light and moisture.

Reconstituted solutions should be used immediately or aliquoted and frozen.

Testing Methods

CJC-1295 batches should be verified by:

RP-HPLC for purity (≥98% recommended)

Mass spectrometry for identity confirmation

Research Limitations

CJC-1295 is supplied for in vitro laboratory research and animal model studies only. Most published research is from animal models. No clinical trials have confirmed efficacy in humans for the applications described. No medical, therapeutic, or dosing claims are made. CJC-1295 is not approved for human therapeutic use by any regulatory authority.

References

1.Jette L, et al. CJC-1295 and GH Release. Endocrinology. 2005;146(7):3265-3272.
2.Teichman SL, et al. CJC-1295 Pharmacology. J Clin Endocrinol Metab. 2006;91(10):4100-4107.
3.Campbell RM, Bongers J. GHRH Analogues. Biopolymers. 2000;51(4):281-296.

Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.